|
|||||
|
|
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia |
|
| Authors: | Peer Cody J Sissung Tristan M Kim Aerang Jain Lokesh Woo Sukyung Gardner Erin R Kirkland C Tyler Troutman Sarah M English Bevin C Richardson Emily D Federspiel Joel Venzon David Dahut William Kohn Elise Kummar Shivaani Yarchoan Robert Giaccone Giuseppe Widemann Brigitte Figg William D |
| Affiliation: | Clinical Pharmacology Program, Pharmacology and Experimental Therapeutics Section, Molecular Pharmacology Section, Biostatistics and Data Management Branch, Medical Oncology Branch, and HIV/AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA. |
| Abstract: | |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |